Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 10/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16615938 | 0.88 | GRIN2A (0.51) | VNN1GAAROCK2GRM5ALDH1A1 | |
| SCHEMBL16615798 | 0.85 | HPGD (0.47) | GAAROCK2ALDH1A1GRIN1GRIN2A | |
| SCHEMBL16615922 | 0.83 | GRIN2A (0.54) | VNN1GAAROCK2GRM5ALDH1A1 | |
| SCHEMBL16713106 | 0.82 | GRIN1 (0.38) | VNN1GRM5GRIN1GRIN2A | |
| SCHEMBL16615844 | 0.81 | EPHX2 (0.51) | ROCK2GRIN1GRIN2A | |
| SCHEMBL16615929 | 0.80 | GRIN2A (0.49) | GAAGRIN1GRIN2A | |
| SCHEMBL16615793 | 0.77 | GRIN2A (0.45) | ALDH1A1GRIN1GRIN2A | |
| SCHEMBL16615790 | 0.76 | VNN1 (0.45) | VNN1GAAROCK2GRM5ALDH1A1 | |
| SCHEMBL16615937 | 0.75 | GRIN2A (0.61) | GRM5ALDH1A1GRIN1GRIN2A | |
| SCHEMBL16615794 | 0.75 | GRIN2A (0.49) | GAAALDH1A1GRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963434-B2 | N-arylmethyl sulfonamide negative modulators of NR2A | LUC THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963434-B2 | N-arylmethyl sulfonamide negative modulators of NR2A | LUC THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20160311782-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160311782-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20150141433-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | MNEMOSYNE PHARMACEUTICALS, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150141433-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | MNEMOSYNE PHARMACEUTICALS, INC. | 2015-05-21 | — | — | US | disclosed |
| WO-2015048503-A2 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | MNEMOSYNE PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311782-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | GRIN2A, GRIN2B, NR2C2 | VNN1 2651/4885GAA 3027/4885ROCK2 4264/4885 |
| US-20150141433-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | GRIN2A, GRIN2B, NR2C2 | VNN1 2651/4885GAA 3027/4885ROCK2 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.